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Preferably, compound D SEQ ID NO:1 is administered in

METHOD FOR TREATING A VIRAL
INFECTION RELATED OR A CHEMICAL
TOXIN RELATED HEPATIC INJURY WITH
DELTORPHIN D

a pharmaceutical composition at a dosage of from about 0.5

mg/kg to about 20 mg/kg per body Weight of the mammal.
Preferably, the mammal is a human.

This application is a divisional of US. application Ser.
No. 09/971,902, ?led Oct. 5, 2001 now US. Pat. No.

DETAILED DESCRIPTION

6,875,742, Which claims the bene?t of US. application Ser.
No. 60/238,991, ?led Oct. 10, 2000, the disclosures ofWhich
are hereby incorporated by reference herein in their entirety.

A compound used to treat cytokine-mediated hepatic
injury is a peptide having the sequence Tyr-D-Leu-Phe-Ala

Asp-Val-Ala-Ser-Thr-Ile-Gly-Asp-Phe-Phe-His-Ser-Ile
NH2 SEQ ID NO: 1, hereinafter referred to compound-D. The

FIELD OF THE INVENTION

peptide may be produced by a number of methods, such as

using an automated peptide synthesiZer, through recombi

The invention relates to the use of compounds to attenuate

nant molecular techniques, or isolated from a naturally
occurring source, as is knoWn to one skilled in the art.

or prevent cytokine mediated hepatic injury.
BACKGROUND
20

Hepatic injury can be caused by a number of different

agents including viruses such as Hepatitis A, B, C, D and E,
both gram positive and gram negative bacteria, chemical
agents such as ethanol, carbon tetrachloride and lead, and by

25

physical trauma resulting in ischemia (ischemic hepatitis)
injuries as can occur in right-sided congestive heart failure.
It is noW believed that all of these types of hepatic injury are
caused at least in part by the liver’s in?ammatory or cytok
ine response to these agents. The in?ammatory response of
the liver results in the overexpression of a cascade of

in?ammatory/acute phase cytokines, such as interleukin-1
(IL-1), tumor necrosis factor (TNF), IL-6, IL-8 and trans
forming groWth factor beta (TGFB). It is noW believed that
it is the cascade of these cytokines Which is the ultimate
cause of much of the hepatic injury resulting from these
agents. Thus, there is a need for a therapeutic agent Which
can be useful in alleviating or modulating the in?ammatory
response associated With liver disease or injury.

may be administered by parenteral means, for example, by
intravenous injection. For administration into a mammal, a
30

dose of about 1-20 milligrams per kilogram (mg/kg) is
useful. For administration into a tissue or organ preservation

solution, a concentration of about 100 uM is useful.

Compound-D SEQ ID NO:1 may be administered directly
35

into a mammal, either alone or in combination With other
substances.
The above agent is administered to a mammal to modulate

40

cytokine activation by blocking one or more steps in the
cytokine cascade. The agent may be formulated for admin
istration in an aqueous based liquid such as phosphate
buffered saline to form an emulsion, or may be formulated
in an organic liquid such as dimethylsulfoxide to form a

SUMMARY OF THE INVENTION

The present invention ?lls this need by providing a
method of treating or preventing a cytokine mediated
hepatic injury in a mammal comprised of administering a
pharmaceutically effective amount of a peptide having the

Compound-D SEQ ID NO:1 has a molecular Weight of
1,902 daltons. Compound-D SEQ ID NO:1 is insoluble in
Water or saline, but may be solubiliZed by adding 100 uM of
a solution comprised of ethanol, propylene glycol, and 1 N
NaOH in a 1:1:1 ratio, With sterile physiological saline then
used to obtain the appropriate concentration. The initial
alkaline pH is adjusted to 7.4 With 1 N HCl.
Compound-D SEQ ID NO:1 that has been solubiliZed

solution. The solution or emulsion may be administered by
45

after referred to as compound D, to said mammal. The
hepatic injury can be an acute in?ammatory reaction, as a

any route, but it is preferably administered parenterally such
as by intravenous, intramuscular, intradermal or intraperi
toneal injections. A preferred dose is in the range of about
0.5-20 mg of compound-D SEQ ID NO:1 per kg of body
Weight of the mammal. The time of administration of the
agent is preferably prior to initiation of cytokine activation.
HoWever, the agent may be administered concurrently With

result of a viral or bacterial infection or a chemical agent

another agent that induces cytokine activation or even

sequence
Tyr-D-Leu-Phe-Ala-Asp-Val-Ala-Ser-Thr-Ile
Gly-Asp-Phe-Phe-His-Ser-Ile-NH2 SEQ ID NO: 1, herein

such as ethanol, lead, carbon tetrachloride or acetami
nophen, or from trauma resulting in ischemia or reperfusion

50

55

injury in the liver.

subsequent to an agent that induces cytokine activation and
still produce a protective effect.
Administration of compound-D SEQ ID NO:1 should be

The present invention is also directed to a method of

continued on a daily basis until hepatic function returns to

treating a viral or bacterial infection-related hepatic damage
in a mammal comprised of administering a pharmaceutically
effective amount of compound D SEQ ID NO: 1 to said
mammal.

normal and is maintained at normal levels, preferably for at
least one to tWo days. Hepatic injury can be determined by
elevated levels of hepatic enZymes, as Well as by depressed

60

The present invention is also directed to a method of

treating alcohol induced liver injury in a mammal comprised
of administering a pharmaceutically effective amount of
compound D SEQ ID NO: 1 to said mammal.

65

albumin levels (less than about 35 g/liter). Hepatic function
is routinely monitored by quantitating serum levels of
hepatic enZymes such as alanine aminotransferase (ALT)

(normal<35 U/L), aspartate aminotransferase (AST) (nor
mal<30 U/L), alkaline phosphatase (ALP) (normalé100

US 7,335,642 B2
3

4

U/L) and gamma glutamyltransferase (GGT) (normalé45
U/L for males, E30 U/L for females), as Well as bilirubin,

Therefore various changes, modi?cations or alterations to
these embodiments may be made or resorted to Without

both conjugated (normal§0.2 mg/deciliter) and total (nor
mal§1.0 mg/deciliter) bilirubin. Compound-D SEQ ID

departing from the spirit of the invention and the scope of
the following claims.

SEQUENCE LISTING

SEQ ID NO 1
LENGTH: 17
TYPE: PRT

ORGANISM: Artificial Sequence
FEATURE:

NAME/KEY: MODiRES
LOCATION:

OTHER

(l) . . . (17)

INFORMATION:

Xaa =

D-Leu; artificial sequence is completely

synthesized
<400> SEQUENCE: l

Tyr Xaa Phe Ala Asp Val Ala Ser Thr Ile Gly Asp Phe Phe His Ser Ile
l

5

l0

25

NOzl modulation of hepatocyte cytokine activation may be
used therapeutically in a variety of hepatic injury processes.
As used herein, the term hepatic injury broadly encompasses
all types of injury such as hepatic trauma, physical and/or
chemical insult, stress, in?ammation, toxicity, disease and so
on. For example, the inventive agents can be used in treating

hepatic injury due to alcoholic liver disease, acetaminophen
toxicity, cadmium toxicity, lead poisoning, bacteremia due
to, for example, Staphylococcus species, Streptococcus spe

What is claimed is:

30

ID NO:1 for a duration su?icient to treat the hepatic injury
related to the viral infection.
2. The method of claim 1 Wherein the viral infection is
35

cies, Neisseria species, Salmonella species, Shigella species,
Escherichia coli, Clostridium perfringens, Klebsiella spe

cies, Proteus species, Enterobacter species, Bacteroides
species, Brucella species, Francisella tularensis, Listeria
monocytogenes, Acinetobacter species, Streptobacillus
moniliformis, Vlbl’lO species, Helicobacter pylori,
Pseudomonas species, Haemophilus species, Bordetella per
tussis, viral infections due to, for example, in?uenza viruses,

adenoviruses, paramyxoviruses, rubella viruses, poliovi

caused by a hepatitis virus.
3. The method of claim 1 Wherein said compound is
administered prior to said hepatic injury related to the viral
infection.
4. The method of claim 1 Wherein said compound is

40

administered subsequent to said hepatic injury related to the
viral infection.
5. The method of claim 1 Wherein said compound is

administered substantially concurrently With said hepatic
45

ruses, hepatitis viruses, herpesviruses, rabies viruses, human
immunode?ciency viruses and papilloma viruses, as Well as

trauma, ischemia reperfusion injury and metabolic liver
disease.

1. A method for treating a viral infection related hepatic
injury in a mammal comprising administering a pharmaceu
tically effective concentration of the peptide shoWn in SEQ

50

injury related to the viral infection.
6. The method of claim 1 Wherein said compound is
administered in the formulation selected from the group
consisting of a solution, an emulsion and a suspension.
7. The method of claim 1 Wherein said compound is

administered parenterally.

While the speci?c mechanism of action of compound-D

8. The method of claim 1 Wherein said compound is

SEQ ID NO:1 on the modulation of cytokine mediated
hepatic injury such as acute in?ammatory reactions, trauma
and toxin induced biological responses is unknown, these
agents exhibit a speci?c and reproducible effect on decreas

administered at a concentration in the range of about 0.5

mg/kg to about 20 mg/kg.
55

ing hepatotoxicity.
A treatment for attenuating and/or preventing cytokine

tically effective concentration of the peptide shoWn in SEQ

mediated acute in?ammatory, trauma induced and toxin

induced hepatic injury is thus disclosed. Compound-D SEQ
ID NO: 1, administered at a concentration of about 0.5 mg/kg

60

to about 20 mg/kg, inhibits hepatic injury and result in
decreased lethality of an injured animal.

are only preferred embodiments of the inventors Who are
skilled in the art and thus are not limiting in any Way.

ID NO:1 for a duration su?icient to treat the hepatic injury

caused by the chemical toxin.
11. The method of claim 10 Wherein the chemical toxin is

selected from the group consisting of ethanol, lead, cad
mium, carbon tetrachloride, and acetaminophen, and com

It should be understood that the embodiments of the

present invention shoWn and described in the speci?cation

9. The method of claim 1 Wherein said compound is
administered at least until hepatic function normaliZes.
10. A method for treating chemical toxin related hepatic
injury in a mammal comprising administering a pharmaceu

65

binations thereof.

